-- SSYグループ（香港証券取引所：2005）は、木曜日に香港証券取引所に提出した書類の中で、中国国家薬品監督管理局からシアノコバラミン（ビタミンB12）注射剤の承認を取得したと発表した。 この承認は、同薬が規制当局によるジェネリック医薬品の品質と有効性に関する一貫性評価に合格したことを受けて得られた。 同社によると、この注射剤は主に神経炎などの内因子欠乏症による巨赤芽球性貧血の治療に用いられる。
Related Articles
International
US Initial Jobless Claims 200,000 Vs. Expected 205,000, Prior 190,000
Research
AlphaMena Upgrades Al-Babtain Power and Telecommunication to Add, Boosts PT
AlphaMena on Thursday upgraded power and telecommunications products company Al-Babtain Power and Telecommunication (SASE:2320) to add from reduce and increased its price target to 75.60 Saudi riyals from 66.30 riyals.(covers equity, commodity and economic research from major banks and research firms in North America, Asia and Europe. Research providers may contact us here: https://www..com/contact-us)
$SASE:2320
Research
Research Alert: Ddog Crushes Expectations As Growth Continues To Accelerate
CFRA, an independent research provider, has providedwith the following research alert. Analysts at CFRA have summarized their opinion as follows:DDOG crushed Q1 expectations with revenue of $1.006B (+32% Y/Y), beating guidance and consensus by approximately $50M, while non-GAAP EPS of $0.60 exceeded Street estimates by $0.09. Large customer growth meaningfully reaccelerated with $100K+ ARR customers growing 21% Y/Y to approximately 4,550, up from 19% in Q4, validating the platform consolidation thesis as enterprises increasingly consolidate observability and security workloads. Management substantially raised FY 26 guidance with revenue now expected at $4.30B-4.34B (vs. prior $4.06B-4.10B and consensus $4.12B), representing 25% growth at midpoint. We believe the strong operational leverage is evident with non-GAAP operating margin expanding 30 bps to 22% despite heavy AI investments. The company's robust $4.8B cash position provides substantial firepower for strategic investments in the rapidly evolving AI infrastructure landscape, while 29% FCF margin demonstrates efficient scaling capabilities.
$DDOG